- Alzheimer's disease
- Bone research
- Brain and CNS
Cancer and inflammation
- Bcl-1 cyclin D1
- COX-1 COX-2
- Fatty acid synthase
- Hepatocyte growth factor
- Intelectin-1 Omentin-1
- Napsin A
- Poly ADP-ribose
- Stem cell factor
- Cell adhesion and ECM
- Environmental hazards
- Epigenetic antibodies
- Metabolic diseases
- mTOR signaling
- Signal transduction
- Stem cell research antibodies
- Virus research
- Miscellaneous research areas
C4.4A protein is a glycosylphosphatidylinositol (GPI)-binding protein encoded by the LYPD3 gene in humans. It contains two urokinase-type plasminogen activator receptor (uPAR) domains and belongs to the Ly6/uPAR/alpha-neurotoxin (LU) domain family. C4.4A was originally identified in studies of rat pancreatic cancer and urothelial cancer. It is expressed in squamous epithelial cells, mostly in esophagus and skin, and in the amnion membrane in placenta.
C4.4A protein is a glycosylphosphatidylinositol (GPI)-binding protein encoded by the LYPD3 gene in humans. It contains two urokinase-type plasminogen activator receptor (uPAR) domains and belongs to the Ly6/uPAR/alpha-neurotoxin (LU) domain family. C4.4A was originally identified in studies of rat pancreatic cancer and urothelial cancer. It is expressed in squamous epithelial cells, mostly in esophagus and skin, and in the amnion membrane in placenta. In humans, C4.4A expression has been reported in malignant melanoma, and urothelial, lung, esophageal, and colon cancers. C4.4A is also known as LY6/PLAUR domain containing 3 (LYPD3), matrigel-induced gene C4 protein (MIG-C4), and GPI-anchored metastasis-associated protein C4.4A homolog.
This product is an affinity-purified IgG antibody that recognizes human C4.4A/LYPD3 protein. The antibody was raised in rabbit using a synthetic peptide and can be used for Western blot (WB) detection or immunohistochemical (IHC) detection of human C4.4A/LYPD3 protein.
- Target Name: Human C4.4A/LYPD3 protein
- Antigen: Human C4.4A/LYPD3 synthetic peptide
- Application: WB, IHC
- Target Entrez Gene ID: 27076
Recommended antibody concentration (the optimal concentration should be determined empirically):
- Western blot: 1–5 µg/ml
- Immunohistochemical techniques: 5 µg/ml
Lyophilized: stable for 5 years at 2–8°C. In solution: stable for 2 years at –20°C.
Lyophilized from an antibody solution containing 1% BSA in PBS and 0.05% NaN3. To use, reconstitute in 1.0 ml H2O (final concentration 50 µg/ml).
LY6/PLAUR domain containing 3, LYPD3, matrigel-induced gene C4 protein, MIG-C4, GPI-anchored metastasis-associated protein C4.4A homolog
Additional product information
Please see the product's Certificate of Analysis for information about storage conditions, product components, and technical specifications. Please see the Kit Components List to determine kit components. Certificates of Analysis and Kit Components Lists are located under the Documents tab.
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2018 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.